RE:RE:RE:RE:RE:RE:RE:Myovant Sciences acquired for $2.9 BLN on second offer Barely $850m for 20 yrs, multiple ph3's and greatly derisked science...when preclinical and early stage biotechs are getting multi billion dollar deals...well, what a waste of time & energy this journey has been...my opinion.